Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review.
| Autor: | Alzaabi MA; Cardiothoracic Surgery, Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates., Abdelsalam A; Department of Cardiology, Al Qassemi Hospital Sharjah, United Arab Emirates., Alhammadi M; College of Medicine, University of Sharjah Sharjah, United Arab Emirates., Bani Hani H; College of Medicine, University of Sharjah Sharjah, United Arab Emirates., Almheiri A; College of Medicine, University of Sharjah Sharjah, United Arab Emirates., Al Matrooshi N; Cardiothoracic Surgery, Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates., Al Zaman K; Cardiothoracic Surgery, Heart, Vascular & Thoracic Institute, Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates.; College of Medicine, University of Sharjah Sharjah, United Arab Emirates. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiac failure review [Card Fail Rev] 2024 Jun 03; Vol. 10, pp. e06. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024). |
| DOI: | 10.15420/cfr.2023.24 |
| Abstrakt: | There is a high prevalence of heart failure (HF) worldwide, which has significant consequences for healthcare costs, patient death and quality of life. Therefore, there has been much focus on finding and using biomarkers for early diagnosis, prognostication and therapy of HF. This overview of the research presents a thorough examination of the current state of HF biomarkers and their many uses. Their function in diagnosing HF, gauging its severity and monitoring its response to therapy are all discussed. Particularly promising in HF diagnosis and risk stratification are the cardiac-specific biomarkers, B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Markers of oxidative stress, extracellular matrix, renal function, inflammation and cardiac peptides have shown promise in evaluating HF severity and prognosis. MicroRNAs and insulin-like growth factor are two emerging biomarkers that have shown potential in helping with HF diagnosis and prognosis. Competing Interests: Disclosure: The authors have no conflicts of interest to declare. (Copyright © The Author(s), 2024. Published by Radcliffe Group Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|